Search

Cabazitaxel

[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376] … [A7056] Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].

Iopodic acid

This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.

Sodium phosphate, dibasic, unspecified form

Deucravacitinib

[L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788]

Belimumab

[L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years.

Certolizumab pegol

[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … [A176606] Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be

Methylenedioxyethamphetamine

Oritavancin

[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion.

Olipudase alfa

[A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022.

Lasofoxifene

It gained approval by European Commission in March 2009.